Clinical Trials
34 trialsCELEBRATE
Peter MacCallum Cancer Centre, Australia
ACTME
Leiden University Medical Center
PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma
Provectus Pharmaceuticals
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma
Keio University
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
Kineta Inc.
ICEMELT
Western Sydney Local Health District
KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma
Shanghai Kanda Biotechnology Co., Ltd.
Nivo-TIL
Nantes University Hospital
A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma
Philogen S.p.A.
CHARLI
Melanoma and Skin Cancer Trials Limited
NeoPepVac
Herlev Hospital
Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors
Beijing Immunochina Medical Science & Technology Co., Ltd.
A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC
Ella Therapeutics Ltd
COMBI-R2
Universitair Ziekenhuis Brussel
SONIMEL01
Assistance Publique - Hôpitaux de Paris
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
TCR
The Netherlands Cancer Institute
A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma
Virogen Biotechnology Inc.
In-hospital Neutron Irradiator (IHNI)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment of Malignant Melanoma
The Third Xiangya Hospital of Central South University
OPTIMUM
Assistance Publique - Hôpitaux de Paris
Safety and Efficacy Study of DCVax-Direct in Solid Tumors
Northwest Biotherapeutics
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
Rutgers, The State University of New Jersey
Vaccine Therapy in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma
National Cancer Institute (NCI)
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
National Cancer Institute (NCI)
Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma
National Cancer Institute (NCI)
Vaccine Therapy in Treating Patients With Stage IV Melanoma
National Cancer Institute (NCI)
Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes
National Cancer Institute (NCI)
THERAVAC
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)
Instituto de Investigação em Imunologia
Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma
National Cancer Institute (NCI)
Survivin Peptide Vaccination for Patients With Advanced Melanoma, Pancreatic, Colon and Cervical Cancer
Julius-Maximilians University
Pain Relief - Tramadol Versus Ibuprofen
Royal Liverpool University Hospital